Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 28:14:73-79.
doi: 10.2147/CIA.S159148. eCollection 2019.

RAB10: an Alzheimer's disease resilience locus and potential drug target

Justina P Tavana  1 , Matthew Rosene  2 , Nick O Jensen  2 , Perry G Ridge  1 , John Sk Kauwe  1   3 , Celeste M Karch  2   4
Affiliations
Review

RAB10: an Alzheimer's disease resilience locus and potential drug target

Justina P Tavana et al. Clin Interv Aging. .

Abstract

Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.

Keywords: APP; Alzheimer’s disease; GTPase; RAB10; resilience; retromer.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Diagram of APP trafficking and the role of RAB10 in these intracellular transport pathways.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;377(77):77sr1. - PMC - PubMed
    1. Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80(6):1347–1358. - PMC - PubMed
    1. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43–51. - PMC - PubMed
    1. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–260. - PMC - PubMed
    1. Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN) Neuropathology. 2015;35(4):390–400. - PMC - PubMed